Adagio Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
As per the lawsuit, the defendants allegedly made false or deceptive statements or failed to reveal that: (1) the epitope mapping, structural studies, and sequence analyses that the defendants relied on to support the effectiveness of ADG20 against Omicron were inadequate, unreliable, and insufficient; (2) the assertions about ADG20’s effectiveness against Omicron lacked a reasonable factual basis; (3) ADG20’s efficacy against the Omicron variant was over 300 times lower compared to its efficacy against earlier variants; and (4) consequently, the Company’s public statements were misleading and false during all the relevant times. The members of the Class have reportedly sustained significant losses due to the defendants’ wrongful actions and omissions, as well as the substantial decline in Invivyd’s common stock market value.
